Moderna receives Investment Bank Analyst Rating Update
- ByInvesting.com-
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to...
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement To date, mRNA-3927 has been generally well-tolerated at the doses administered,...
Moderna (NASDAQ:MRNA) shares opened higher Thursday on the back of its surprising earnings and revenue beat. The drugmaker had been expected to post a $1.75 loss in the...
Investing.com - Moderna (NASDAQ: MRNA) reported first quarter EPS of $0.19, $1.94 better than the analyst estimate of $-1.75. Revenue for the quarter came in at $1.9B versus the...
Investing.com -- Stocks in focus in premarket trade on Thursday, May 4th. Please refresh for updates. PacWest Bancorp (NASDAQ:PACW) stock fell 40% after the regional lender...
Investing.com -- U.S. stocks are seen opening in a subdued fashion Thursday as investors digest the Federal Reserve’s latest policy move as well as more turmoil in the...
Investing.com - U.S. stock futures were trading lower during Wednesday's evening deals, after major benchmark indices extended declines during the regular session, with Federal...
Investing.com -- First Republic Bank has been taken over by Californian authorities with JPMorgan Chase assuming its deposits, at the start of a week that includes a Federal...